At 6.6% CAGR, the North America CIN & HR-HPV Treatment Market is projected to be worth US$ 6,693.51million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the North America CIN & HR-HPV treatment market was valued at US$ 4,872.99 million in 2023 and is expected to reach US$ 6,693.51million by 2028, registering a CAGR of 6.6% from 2023 to 2028. Increase in prevalence of human papillomavirus infections and favorable initiatives of preventing cervical cancer are the critical factors attributed to the North America CIN & HR-HPV treatment market expansion. 

Cervical intraepithelial neoplasia (CIN), also called cervical dysplasia, is characterized by the formation of proliferative lesions with abnormal cell growth on the surface of the cervix. These lesions replace a part of or the entire cervical squamous epithelium, and they are perceived as precursors of cervical cancer. Cervical dysplasia is caused by human papillomavirus (HPV) infection. Over 200 variants of HPV are known to cause infections among humans, and ~40 of these variants affect genitals upon spreading through sexual contact. 12 of these HPV types are associated with a high risk of cancer, and ~10 are associated with low risk cancer. ~70% of cervical cancer cases are caused by HPV type 16 and type 18, which are high-risk HPV (HR-HPV) serotypes. According to the American Cancer Society, 9 out of 10 cervical cancers are caused by HPV; in 2023, ~13,960 women in the US are likely to be diagnosed with cervical cancer, and the disease is expected to cause death among ~4,310 women. According to a study published in the National Library of Medicine, in 2022, most cervical cancer cases were caused by HPV 16, accounting for 55–60% of cervical cancer cases reported across the region in that year.. A persistent HPV infection can result in CIN among subjects that are immunocompromised and infected with HIV and have a history of smoking.

According to the Centers for Disease Control and Prevention (CDC), cervical cancer due to HPV infection is the ninth most common cancer among women in the US, and each year, ~13 million people are infected with HPV infection. According to the HPV Information Center, US, in 2023, ~3.9% of women are likely to be infected with cervical HPV16 or 18, and 71.2% of cervical cancers are attributed to HPVs 16 or 18

Thus, a rise in the prevalence of HPV infections contributes to the growth of the CIN & HR-HPV treatment market.

On the contrary, Increased Reoccurrence Rate and High Cost of CIN & HR-HPV Treatment hurdles the growth of North America CIN & HR-HPV Treatment Market

Based on disease type, the North America CIN & HR-HPV treatment market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment held 46.1% market share in 2023, amassing US$ 2,245.71 million. It is projected to garner US$ 3,209.67 million by 2028 to expand at 7.4% CAGR during 2023–2028.

Based on strain type, the North America CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held 62.2% market share in 2023, amassing US$ 3,030.25 million. It is projected to garner US$ 4,169.48 million by 2028 to expand at 6.6% CAGR during 2023–2028.

Based on offering, the North America CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held 72.1% market share in North America CIN & HR-HPV treatment market in 2023, amassing US$ 3,514.91 million. It is projected to garner US$ 4,704.06 million by 2028 to expand at 6.0% CAGR during 2023–2028. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the North America CIN & HR-HPV treatment market is segmented into kits & reagents, instruments, and services. The services segment held 59.4% market share in 2023, amassing US$ 2,892.31 million. It is projected to garner US$ 3,992.93 million by 2028 to expand at 6.7% CAGR during 2023–2028.

Based on end user, the North America CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held 45.6% market share in 2023, amassing US$ 2,221.44 million. It is projected to garner US$ 3,006.16 million by 2028 to expand at 6.2% CAGR during 2023–2028.

Based on country, the North America CIN & HR-HPV treatment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.5% market share in North America CIN & HR-HPV treatment market in 2023. It was assessed at US$ 4,021.44million in 2023 and is likely to hit US$ 5,535.60 million by 2028, exhibiting a CAGR of 6.6% during the forecast period.     

Key players dominating the North America CIN & HR-HPV treatment market are Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; Cepheid; F. Hoffmann-LA Roche Ltd; INOVIO Pharmaceuticals Inc; Bioneer Corp; Antiva Biosciences Inc; and Thermo Fisher Scientific Inc among others.   

• In Oct 2022, Fujirebio Europe receives distribution rights.
• In Feb 2021, QIAGEN and INOVIO expand collaboration.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com